Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Improved prognostic stratification including imaging-based parameters is needed to guide treatment decisions in IDH-mutant glioma.
Methods: In this bicentric retrospective study, 457 patients with IDH-mutant glioma and [18F]fluoroethyltyrosine or [11C]methionine positron emission tomography (PET) prior to radiotherapy or systemic treatment were included. Associations of maximum and mean tumor-to-background ratios (TBRmax/TBRmean) and PET-positive volume (PET volume) with time to next intervention (TTNI) and overall survival (OS) were analyzed.
Results: Overall, 251 (54.9%) patients with astrocytoma and 206 (45.1%) with oligodendroglioma were included. In patients with astrocytoma who underwent PET before resection, measurable disease according to PET RANO 1.0 criteria was associated with shorter TTNI compared to no/non-measurable disease (median 46.0 vs. 67.9 months; p=0.004). Univariable analysis showed an association of TTNI with TBRmax, TBRmean and PET volume in astrocytoma and PET volume in oligodendroglioma. Multivariable analyses including age, WHO grade, extent of resection, postoperative treatment and magnetic resonance imaging (MRI)-based tumor extent indicated an association of TTNI with TBRmax (HR 1.48 [95%CI: 1.09-2.01]) and TBRmean (HR 1.93 [95%CI: 1.14-3.27]) in astrocytoma and PET volume (HR [10 ml increase]: 1.18 [95%CI: 1.03-1.36]) in oligodendroglioma. In astrocytoma, also OS was related to TBRmax (HR: 1.40 [95%CI: 1.13-1.74]), TBRmean (HR: 1.97 [95%CI: 1.21-3.22]), and PET volume (HR: 1.23 [95%CI: 1.10-1.37]) in univariable analysis. Further analyses considering timepoint of PET showed consistent results.
Conclusions: In this retrospective study, amino acid PET parameters were associated with outcome in newly diagnosed IDH-mutant glioma. Future clinical trials should include PET imaging to define imaging-based prognostic signatures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/neuonc/noaf196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [F]FDG PET/CT study.
Eur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFQuantification of monoamine oxidase B expression with C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer's disease.
Eur J Nucl Med Mol Imaging
September 2025
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Purpose: Astrocyte reactivation can be assessed using positron emission tomography (PET) ligands targeting monoamine oxidase B (MAO-B). C-SL25.1188 binds reversibly to MAO-B, allowing precise density measurements, but requires invasive arterial sampling.
View Article and Find Full Text PDFThe Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
J Urol
September 2025
Department of Urology, Austin Health, Melbourne, Victoria, Australia.
Purpose: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly used to diagnose and stage prostate cancer. A PRIMARY score uses anatomical localization and uptake patterns to improve diagnostic accuracy. We evaluated the histopathology of patients with no uptake pattern (PRIMARY score 1) and the prevalence of intraductal carcinoma of the prostate (IDC-P) in this subset compared with those with an uptake pattern (PRIMARY score ≥ 2).
View Article and Find Full Text PDFComparison of different response evaluation criteria in interim PET/computed tomography for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?
Nucl Med Commun
September 2025
Department of Pathology, Ministry of Health Bingol State Hospital, Bingol, Turkey.
Objective: This study aimed to evaluate the most reliable predictors of progression-free survival (PFS) and overall survival (OS) among six different response criteria during interim PET (I-PET)/computed tomography (CT), including the change in total metabolic tumor volume (ΔTMTV) in patients with diffuse large B-cell lymphoma (DLBCL).
Methods: A retrospective analysis was conducted on patients with DLBCL who underwent baseline PET/CT and I-PET after 3-4 cycles of chemoimmunotherapy. Various response criteria were assessed, including Lugano, response evaluation criteria in lymphoma (RECIL), change in maximum standardized uptake value (ΔSUVmax), Peking, quantitative PET, and the novel ΔTMTV.
Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.
ESC Heart Fail
September 2025
Division of Cardiology, Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Aims: Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long-acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family peptide receptor 1 (RXFP1), showed trends of increased stroke volume and estimated glomerular filtration rate (eGFR) in HF patients (NCT04630067).
View Article and Find Full Text PDF